Exacerbations and health care resource use among patients with COPD in relation to blood eosinophil counts
Hana Müllerová,1 Beth Hahn,2 Edgar P Simard,3 George Mu,3 Umur Hatipoğlu4 1Real-World Evidence, GSK, Stockley Park, Uxbridge, Middlesex, UK; 2US Medical Affairs, GSK, Research Triangle Park, NC, USA; 3Real-World Data and Analytics, GSK, Upper Providence, PA, USA; 4Center for Comp...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-03-01
|
| Series: | International Journal of COPD |
| Subjects: | |
| Online Access: | https://www.dovepress.com/exacerbations-and-health-care-resource-use-among-patients-with-copd-in-peer-reviewed-article-COPD |
| _version_ | 1819198872104206336 |
|---|---|
| author | Müllerová H Hahn B Simard EP Mu G Hatipoğlu U |
| author_facet | Müllerová H Hahn B Simard EP Mu G Hatipoğlu U |
| author_sort | Müllerová H |
| collection | DOAJ |
| description | Hana Müllerová,1 Beth Hahn,2 Edgar P Simard,3 George Mu,3 Umur Hatipoğlu4 1Real-World Evidence, GSK, Stockley Park, Uxbridge, Middlesex, UK; 2US Medical Affairs, GSK, Research Triangle Park, NC, USA; 3Real-World Data and Analytics, GSK, Upper Providence, PA, USA; 4Center for Comprehensive Care in Chronic Obstructive Pulmonary Disease, Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA Purpose: Current understanding of the relationship between COPD phenotype and health care resource utilization (HCRU) is limited. This real-world study evaluated disease burden and HCRU for COPD subgroups prone to exacerbation as defined by blood eosinophil (EOS) count and multiple inhaler triple therapy (MITT) use.Methods: This was a large-scale, retrospective, longitudinal, observational cohort study using data from the US IBM Watson Explorys real-world database (GSK Study HO-17-18395). The population of interest comprised patients with COPD ≥40 years of age with ≥2 moderate or ≥1 severe exacerbations (prior year) while on inhaled maintenance therapy, with ≥1 blood EOS count. Data were analyzed during the year prior to index date (last COPD encounter between January 1, 2011 and December 31, 2016). Four subgroups were analyzed based on a combination of EOS counts (<150 and ≥150 cells/μL) and MITT use (receiving or not receiving). Among these groups, clinical characteristics, exacerbations, and HCRU were described. A sensitivity analysis that further stratified EOS into four categories (<150, ≥150–<300, ≥300–<500, and ≥500 cells/μL) was also performed.Results: The COPD population of interest comprised 34,268 patients. Subgroups with EOS ≥150 cells/µL vs ,150 cells/µL had more comorbidities and experienced significantly higher mean numbers of moderate exacerbations (not receiving MITT, ≥150 cells/µL vs <150 cells/µL: 1.93 vs 1.82, P<0.0001; receiving MITT 2.26 vs 2.16, P=0.0062) and COPDrelated emergency visits (not receiving MITT, ≥150 cells/µL vs <150 cells/µL: 3.0 vs 2.5, P<0.001; receiving MITT 3.4 vs 3.1, P=0.0011). Increasing EOS category was associated with higher HCRU.Conclusion: Blood EOS ≥150/µL cells were associated with increased HCRU and higher exacerbation rates compared with EOS <150 cells/μL, irrespective of MITT use. COPD phenotyping using blood EOS could help identify candidates for additional therapies that targeteosinophilic inflammatory pathways. Keywords: COPD, eosinophil, exacerbation, health care resource, phenotype |
| first_indexed | 2024-12-23T03:07:20Z |
| format | Article |
| id | doaj.art-4760f0350d67439cac557c946764ca26 |
| institution | Directory Open Access Journal |
| issn | 1178-2005 |
| language | English |
| last_indexed | 2024-12-23T03:07:20Z |
| publishDate | 2019-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of COPD |
| spelling | doaj.art-4760f0350d67439cac557c946764ca262022-12-21T18:02:17ZengDove Medical PressInternational Journal of COPD1178-20052019-03-01Volume 1468369244711Exacerbations and health care resource use among patients with COPD in relation to blood eosinophil countsMüllerová HHahn BSimard EPMu GHatipoğlu UHana Müllerová,1 Beth Hahn,2 Edgar P Simard,3 George Mu,3 Umur Hatipoğlu4 1Real-World Evidence, GSK, Stockley Park, Uxbridge, Middlesex, UK; 2US Medical Affairs, GSK, Research Triangle Park, NC, USA; 3Real-World Data and Analytics, GSK, Upper Providence, PA, USA; 4Center for Comprehensive Care in Chronic Obstructive Pulmonary Disease, Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA Purpose: Current understanding of the relationship between COPD phenotype and health care resource utilization (HCRU) is limited. This real-world study evaluated disease burden and HCRU for COPD subgroups prone to exacerbation as defined by blood eosinophil (EOS) count and multiple inhaler triple therapy (MITT) use.Methods: This was a large-scale, retrospective, longitudinal, observational cohort study using data from the US IBM Watson Explorys real-world database (GSK Study HO-17-18395). The population of interest comprised patients with COPD ≥40 years of age with ≥2 moderate or ≥1 severe exacerbations (prior year) while on inhaled maintenance therapy, with ≥1 blood EOS count. Data were analyzed during the year prior to index date (last COPD encounter between January 1, 2011 and December 31, 2016). Four subgroups were analyzed based on a combination of EOS counts (<150 and ≥150 cells/μL) and MITT use (receiving or not receiving). Among these groups, clinical characteristics, exacerbations, and HCRU were described. A sensitivity analysis that further stratified EOS into four categories (<150, ≥150–<300, ≥300–<500, and ≥500 cells/μL) was also performed.Results: The COPD population of interest comprised 34,268 patients. Subgroups with EOS ≥150 cells/µL vs ,150 cells/µL had more comorbidities and experienced significantly higher mean numbers of moderate exacerbations (not receiving MITT, ≥150 cells/µL vs <150 cells/µL: 1.93 vs 1.82, P<0.0001; receiving MITT 2.26 vs 2.16, P=0.0062) and COPDrelated emergency visits (not receiving MITT, ≥150 cells/µL vs <150 cells/µL: 3.0 vs 2.5, P<0.001; receiving MITT 3.4 vs 3.1, P=0.0011). Increasing EOS category was associated with higher HCRU.Conclusion: Blood EOS ≥150/µL cells were associated with increased HCRU and higher exacerbation rates compared with EOS <150 cells/μL, irrespective of MITT use. COPD phenotyping using blood EOS could help identify candidates for additional therapies that targeteosinophilic inflammatory pathways. Keywords: COPD, eosinophil, exacerbation, health care resource, phenotypehttps://www.dovepress.com/exacerbations-and-health-care-resource-use-among-patients-with-copd-in-peer-reviewed-article-COPDCOPDeosinophilexacerbationhealthcare resourcephenotype |
| spellingShingle | Müllerová H Hahn B Simard EP Mu G Hatipoğlu U Exacerbations and health care resource use among patients with COPD in relation to blood eosinophil counts International Journal of COPD COPD eosinophil exacerbation healthcare resource phenotype |
| title | Exacerbations and health care resource use among patients with COPD in relation to blood eosinophil counts |
| title_full | Exacerbations and health care resource use among patients with COPD in relation to blood eosinophil counts |
| title_fullStr | Exacerbations and health care resource use among patients with COPD in relation to blood eosinophil counts |
| title_full_unstemmed | Exacerbations and health care resource use among patients with COPD in relation to blood eosinophil counts |
| title_short | Exacerbations and health care resource use among patients with COPD in relation to blood eosinophil counts |
| title_sort | exacerbations and health care resource use among patients with copd in relation to blood eosinophil counts |
| topic | COPD eosinophil exacerbation healthcare resource phenotype |
| url | https://www.dovepress.com/exacerbations-and-health-care-resource-use-among-patients-with-copd-in-peer-reviewed-article-COPD |
| work_keys_str_mv | AT mullerovah exacerbationsandhealthcareresourceuseamongpatientswithcopdinrelationtobloodeosinophilcounts AT hahnb exacerbationsandhealthcareresourceuseamongpatientswithcopdinrelationtobloodeosinophilcounts AT simardep exacerbationsandhealthcareresourceuseamongpatientswithcopdinrelationtobloodeosinophilcounts AT mug exacerbationsandhealthcareresourceuseamongpatientswithcopdinrelationtobloodeosinophilcounts AT hatipogluu exacerbationsandhealthcareresourceuseamongpatientswithcopdinrelationtobloodeosinophilcounts |